Skip to content
Search

Latest Stories

Submit Guest Post

CMA to tackle COVID-19 profiteering

THE Competition and Markets Authority (CMA) has launched a taskforce to tackle unscrupulous business practices during the COVID-19 crisis.

The UK’s competition watchdog has earlier this month asked retailers to not exploit the current situation to take advantage of people, warning against practices like charging excessive prices or making misleading claims about their products.


The CMA said it has already contacted traders and platforms regarding excessive pricing of hand sanitiser.

Andrew Tyrie, the CMA chairman said: “The intervention in the economy necessitated by public health policy may have a substantial impact on competition, with the risk of an increase in consumer detriment. That’s why this taskforce is needed.”

CMA chief executive Andrea Coscelli noted: “We have a range of options at our disposal, from warnings to enforcement action to seeking emergency powers. We hope that such action will not be necessary, but we will do whatever is required to stop a small minority of businesses that may seek to exploit the present situation.”

The taskforce will identify harmful sales and pricing practices as they emerge and warn firms suspected of exploiting these exceptional circumstances through unjustifiable prices or misleading claims.

It will also take enforcement action if there is evidence that firms may have breached competition or consumer protection law and fail to respond to warnings.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

Weekly insulin jab

A weekly insulin jab could reduce the burden of daily injections for some people with type 2 diabetes

iStock

From 365 injections to 52: New weekly insulin jab could make life easier for patients

  • The treatment could reduce insulin injections from 365 a year to just 52.
  • NICE has recommended the weekly treatment, but it still needs MHRA approval.
  • People who rely on carers or struggle with daily injections could benefit most.

For some people with type 2 diabetes, managing their condition could soon involve one insulin injection a week instead of one every day.

The National Institute for Health and Care Excellence (NICE) has recommended insulin efsitora alfa, also known as Onswik and made by Eli Lilly, in its final draft guidance. If approved by the medicines regulator and subsequently rolled out on the NHS, the treatment could reduce the number of annual insulin injections from 365 to 52.

Keep ReadingShow less